Acute migraine treatment | UBRELVY® (ubrogepant)

strike down tozero migraine pain with ubrelvy®

Migraine attacks can be unpredictable.³
Make sure your patients are ready.

UBRELVY 100 mg TABLETS ARE AVAILABLE IN A
16-COUNT PACKAGE

Eligible patients may pay as little as
$0—ALL PILLS, ALL FILLS.*

see dosing

Number 1 prescribed branded treatment for migraine attacks icon As of 04/22.^1,2

Order Samples Now!

RAPIDPain relief at 2 hours was demonstrated in 62% (UBRELVY 50 mg) vs 49% (placebo) when taken immediately or within 4 hours of onset^4,5

Learn More

POWERFULPain freedom at 2 hours (primary endpoint) was demonstrated in 21% (UBRELVY 50 mg) vs 13% (placebo).⁴ Sustained pain freedom from 2 to 24 hours (secondary endpoint) was achieved in 14% (UBRELVY 50 mg) vs 8% (placebo)¹

Learn More

PROVENUBRELVY has been prescribed over 2 million times by more than 80,000 physicians, treating over 500,000 patients⁴

Learn More

*Patient out-of-pocket costs may vary. Terms and Conditions apply. This offer is only valid for commercially insured patients. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. Please see full Program Terms, Conditions, and Eligibility Criteria.

References

1. UBRELVY. Package insert. Allergan USA, Inc.; 2021. 2. Retail monthly prescription data from IQVIA on a 6-month rolling basis as of 04/22. 3. Serrano D, Lipton RB, Scher AI, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 2017;18:101. 4. Data on file. Allergan. 5. Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887-1898.